DMK
BMY.RT

David M. Knott’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

David M. Knott’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-64,720
Closed -$45K – 146
2020
Q4 		$45K Buy
64,720
+59,520
+1,145% +$127K 0.02% 92
2020
Q3 		$12K Buy
+5,200
New +$14.8K 0.01% 91
2020
Q1 		– Sell
-15,847
Closed -$48K – 125
2019
Q4 		$48K Buy
+15,847
New +$41.2K 0.02% 101

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

David M. Knott's BMY.RT Position: Q1 2021 in Review

David M. Knott sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 64,720 shares — an estimated $45K sold.

David M. Knott first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $48K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • David M. Knott reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • David M. Knott sold 64,720 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $45K.
  • David M. Knott first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
  • David M. Knott's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $48K in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on David M. Knott's 13F filing for Q1 2021, filed 13 May 2021.